Clinical Trial Update: Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors [Phase 3]

View source ↗

Summary

Phase III study results for surufatinib in advanced extrapancreatic neuroendocrine tumors have been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Surufatinib (Surufatinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Neuroendocrine Tumors | Phase 3 | Status: COMPLETED